Drug intelligence / Profile preview

PvHMB-CCE002

Development stage: Unknown
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

PvHMB-CCE002 is an investigational biological challenge agent used in controlled human malaria infection (CHMI) studies for Plasmodium vivax. The agent consists of a mixture of infected and uninfected erythrocytes stabilized in glycerolyte, designed to induce blood-stage P. vivax malaria in healthy volunteers for research purposes. It is not a therapeutic or prophylactic drug but rather a tool to facilitate the study of malaria pathogenesis, immunity, and the evaluation of candidate vaccines or antimalarial drugs[1][2].

Beyond the preview

Go deeper on PvHMB-CCE002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PvHMB-CCE002.

Explore the full profile